US6982260B1
(en)
|
1999-11-22 |
2006-01-03 |
Warner-Lambert Company |
Quinazolines and their use for inhibiting cyclin-dependent kinase enzymes
|
US7473691B2
(en)
*
|
2000-09-15 |
2009-01-06 |
Vertex Pharmaceuticals Incorporated |
Pyrazole compounds useful as protein kinase inhibitors
|
US6660731B2
(en)
*
|
2000-09-15 |
2003-12-09 |
Vertex Pharmaceuticals Incorporated |
Pyrazole compounds useful as protein kinase inhibitors
|
ATE326458T1
(en)
|
2000-09-15 |
2006-06-15 |
Vertex Pharma |
PYRAZOLE COMPOUNDS AS PROTEIN KINASE INHIBITORS
|
JP4377583B2
(en)
*
|
2000-12-05 |
2009-12-02 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
Inhibitors of C-JUNN terminal kinase (JNK) and other protein kinases
|
DK1353916T3
(en)
*
|
2000-12-21 |
2007-01-29 |
Vertex Pharma |
Pyrazole Compounds Suitable as Protein Kinase Inhibitors
|
CA2441492C
(en)
*
|
2001-03-23 |
2011-08-09 |
Bayer Corporation |
Rho-kinase inhibitors
|
AU2002252614B2
(en)
|
2001-04-10 |
2006-09-14 |
Merck Sharp & Dohme Corp. |
Inhibitors of Akt activity
|
US7105667B2
(en)
*
|
2001-05-01 |
2006-09-12 |
Bristol-Myers Squibb Co. |
Fused heterocyclic compounds and use thereof
|
US7138404B2
(en)
*
|
2001-05-23 |
2006-11-21 |
Hoffmann-La Roche Inc. |
4-aminopyrimidine derivatives
|
US6939874B2
(en)
|
2001-08-22 |
2005-09-06 |
Amgen Inc. |
Substituted pyrimidinyl derivatives and methods of use
|
US7115617B2
(en)
|
2001-08-22 |
2006-10-03 |
Amgen Inc. |
Amino-substituted pyrimidinyl derivatives and methods of use
|
WO2003026664A1
(en)
*
|
2001-09-26 |
2003-04-03 |
Bayer Corporation |
2-phenylamino-4- (5-pyrazolylamino) -pyramidine derivatives as kinase inhibitors, in particular, src kinase inhibitors
|
EA007430B1
(en)
|
2001-09-26 |
2006-10-27 |
Фармация Италия С.П.А. |
Aminoindazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them
|
SE0104140D0
(en)
|
2001-12-07 |
2001-12-07 |
Astrazeneca Ab |
Novel Compounds
|
US20030187026A1
(en)
|
2001-12-13 |
2003-10-02 |
Qun Li |
Kinase inhibitors
|
AU2002361846A1
(en)
*
|
2001-12-21 |
2003-07-15 |
Bayer Pharmaceuticals Corporation |
Quinazoline and quinoline derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents
|
CA2471565C
(en)
*
|
2002-01-10 |
2009-10-27 |
Patricia Ann Day-Lollini |
Use of a gsk-3beta inhibitor in the manufacture of a medicament for increasing bone formation
|
TWI329105B
(en)
|
2002-02-01 |
2010-08-21 |
Rigel Pharmaceuticals Inc |
2,4-pyrimidinediamine compounds and their uses
|
SG159380A1
(en)
*
|
2002-02-06 |
2010-03-30 |
Vertex Pharma |
Heteroaryl compounds useful as inhibitors of gsk-3
|
EP1485100B1
(en)
|
2002-03-15 |
2010-05-05 |
Vertex Pharmaceuticals Incorporated |
Azinylaminoazoles as inhibitors of protein kinases
|
ATE433973T1
(en)
*
|
2002-03-15 |
2009-07-15 |
Vertex Pharma |
AZOLYLAMINOAZINES AS INHIBITORS OF PROTEIN KINASES
|
US20040009981A1
(en)
|
2002-03-15 |
2004-01-15 |
David Bebbington |
Compositions useful as inhibitors of protein kinases
|
WO2003086394A1
(en)
|
2002-04-08 |
2003-10-23 |
Merck & Co., Inc. |
Inhibitors of akt activity
|
US7524852B2
(en)
|
2002-06-07 |
2009-04-28 |
Kyowa Hakko Kogyo Co., Ltd. |
Bicyclic pyrimidine derivatives
|
MY141867A
(en)
|
2002-06-20 |
2010-07-16 |
Vertex Pharma |
Substituted pyrimidines useful as protein kinase inhibitors
|
AU2003261204A1
(en)
*
|
2002-07-23 |
2004-02-09 |
Smithkline Beecham Corporation |
Pyrazolopyrimidines as kinase inhibitors
|
ES2337782T3
(en)
|
2002-07-29 |
2010-04-29 |
Rigel Pharmaceuticals, Inc. |
METHODS TO TREAT OR PREVENT AUTOIMMUNITY DISEASES WITH 2,4-PYRIMIDINDIAMINE COMPOUNDS.
|
CN101037438A
(en)
*
|
2002-08-02 |
2007-09-19 |
沃泰克斯药物股份有限公司 |
Compositions useful as inhibitors of GSK-3
|
EP1739087A1
(en)
*
|
2002-08-02 |
2007-01-03 |
Vertex Pharmaceuticals Incorporated |
Pyrazole compositions useful as inhibitors of gsk-3
|
JP4648703B2
(en)
|
2002-09-05 |
2011-03-09 |
アベンティス・ファーマ・ソシエテ・アノニム |
Novel aminoindazole derivatives as pharmaceuticals and pharmaceutical compositions containing them
|
FR2844267B1
(en)
*
|
2002-09-05 |
2008-02-15 |
Aventis Pharma Sa |
NOVEL DERIVATIVES OF AMINOINDAZOLES AS MEDICAMENTS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM
|
WO2004030672A1
(en)
*
|
2002-10-02 |
2004-04-15 |
Merck Patent Gmbh |
Use of 4 amino-quinazolines as anti cancer agents
|
ES2440217T3
(en)
*
|
2002-10-04 |
2014-01-28 |
Prana Biotechnology Limited |
Neurologically active compounds
|
KR100490893B1
(en)
*
|
2002-10-11 |
2005-05-23 |
(주) 비엔씨바이오팜 |
2-methoxy-1,3,5-triazine derivatives, method for preparing thereof and antiviral pharmaceutical composition comprising the same
|
GB0226583D0
(en)
*
|
2002-11-14 |
2002-12-18 |
Cyclacel Ltd |
Compounds
|
FR2847253B1
(en)
*
|
2002-11-19 |
2007-05-18 |
Aventis Pharma Sa |
NOVEL DERIVATIVES OF PYRIDAZINONES AS MEDICAMENTS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM
|
US7462613B2
(en)
|
2002-11-19 |
2008-12-09 |
Sanofi-Aventis Deutschland Gmbh |
Pyridazinone derivatives as pharmaceuticals and pharmaceutical compositions containing them
|
US7309701B2
(en)
|
2002-11-19 |
2007-12-18 |
Sanofi-Aventis Deutschland Gmbh |
Pyridazinone derivatives as pharmaceuticals and pharmaceutical compositions containing them
|
PL377821A1
(en)
*
|
2002-11-21 |
2006-02-20 |
Chiron Corporation |
2,4,6-trisubstituted pyrimidines as phosphotidylinositol (pi) 3-kinase inhibitors and their use in the treatment of cancer
|
US7601718B2
(en)
*
|
2003-02-06 |
2009-10-13 |
Vertex Pharmaceuticals Incorporated |
Compositions useful as inhibitors of protein kinases
|
US7157455B2
(en)
*
|
2003-02-10 |
2007-01-02 |
Hoffmann-La Roche Inc. |
4-Aminopyrimidine-5-one derivatives
|
EP1644338A1
(en)
*
|
2003-04-01 |
2006-04-12 |
Aponetics AG |
2, 4, 6-trisubstituted pyrimidine derivatives useful for the treatment of neoplastic and autoimmune diseases
|
WO2004105764A1
(en)
*
|
2003-06-02 |
2004-12-09 |
Astrazeneca Ab |
(3- ((quinazolin-4-yl) amino )-1h-pyrazol-1-yl) acetamide derivatives and related compounds as aurora kinase inhibitors for the treatment of proliferative diseases such as cancer
|
EP1633740B1
(en)
*
|
2003-06-19 |
2011-11-09 |
GlaxoSmithKline LLC |
5-(acylamino)indazole derivatives as kinase inhibitors
|
US8309562B2
(en)
|
2003-07-03 |
2012-11-13 |
Myrexis, Inc. |
Compounds and therapeutical use thereof
|
TWI372050B
(en)
*
|
2003-07-03 |
2012-09-11 |
Astex Therapeutics Ltd |
(morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles
|
JP5129957B2
(en)
*
|
2003-07-03 |
2013-01-30 |
ミリアド ジェネティクス, インコーポレイテッド |
4-Arylamino-quinazolines as caspase activators and inducers of apoptosis
|
GB0315966D0
(en)
*
|
2003-07-08 |
2003-08-13 |
Cyclacel Ltd |
Compounds
|
PL2256106T3
(en)
|
2003-07-22 |
2015-08-31 |
Astex Therapeutics Ltd |
3,4-disubstituted 1H-pyrazole compounds and their use as cyclin dependent kinases (CDK) and glycogen synthase kinase-3 (GSK-3) modulators
|
JP2007500179A
(en)
*
|
2003-07-30 |
2007-01-11 |
サイクラセル・リミテッド |
2-Aminophenyl-4-phenylpyrimidine as a kinase inhibitor
|
ES2421139T3
(en)
|
2003-07-30 |
2013-08-29 |
Rigel Pharmaceuticals, Inc. |
2,4-Pyrimidinediamine compounds for use in the treatment or prevention of autoimmune diseases
|
US20050221357A1
(en)
*
|
2003-09-19 |
2005-10-06 |
Mark Shannon |
Normalization of gene expression data
|
US7417726B2
(en)
*
|
2003-09-19 |
2008-08-26 |
Applied Biosystems Inc. |
Normalization of data using controls
|
US20060024690A1
(en)
*
|
2003-09-19 |
2006-02-02 |
Kao H P |
Normalization of data using controls
|
WO2005030131A2
(en)
*
|
2003-09-23 |
2005-04-07 |
Replidyne, Inc |
Bis-quinazoline compounds for the treatment of bacterial infections
|
DE602004022187D1
(en)
|
2003-10-17 |
2009-09-03 |
Astrazeneca Ab |
4- (PYRAZOL-3-YLAMINO) PYRIMIDINE DERIVATIVES FOR USE IN THE TREATMENT OF CANCER
|
WO2005056547A2
(en)
*
|
2003-12-04 |
2005-06-23 |
Vertex Pharmaceuticals Incorporated |
Quinoxalines useful as inhibitors of protein kinases
|
WO2005056552A1
(en)
*
|
2003-12-09 |
2005-06-23 |
Vertex Pharmaceuticals Incorporated |
Naphthyridine derivatives and their use as modulators of muscarinic receptors
|
EP1694686A1
(en)
|
2003-12-19 |
2006-08-30 |
Takeda San Diego, Inc. |
Kinase inhibitors
|
TW200530235A
(en)
|
2003-12-24 |
2005-09-16 |
Renovis Inc |
Bicycloheteroarylamine compounds as ion channel ligands and uses thereof
|
WO2005077938A1
(en)
*
|
2004-02-11 |
2005-08-25 |
Amgen Inc. |
Vanilloid receptor ligands and their use in treatments
|
US20080050314A1
(en)
*
|
2004-02-26 |
2008-02-28 |
Bayer Healthcare Ag |
Diagnostics and Therapeutics for Diseases Associated With Glycogen Synthase Kinase 3 Beta (Gsk3b)
|
EP1726580A4
(en)
*
|
2004-03-15 |
2008-02-13 |
Takeda Pharmaceutical |
Aminophenylpropanoic acid derivative
|
JP4790703B2
(en)
*
|
2004-04-07 |
2011-10-12 |
武田薬品工業株式会社 |
Cyclic compounds
|
US20090227648A1
(en)
*
|
2004-04-21 |
2009-09-10 |
Astrazeneca Ab |
Pyrazole derivatives useful for the treatment of cancer
|
US20050250829A1
(en)
*
|
2004-04-23 |
2005-11-10 |
Takeda San Diego, Inc. |
Kinase inhibitors
|
JP5097539B2
(en)
*
|
2004-05-07 |
2012-12-12 |
アムジエン・インコーポレーテツド |
Protein kinase modulators and methods of use
|
US7793137B2
(en)
|
2004-10-07 |
2010-09-07 |
Cisco Technology, Inc. |
Redundant power and data in a wired data telecommunincations network
|
AU2012200416B2
(en)
*
|
2004-05-14 |
2014-07-31 |
Millennium Pharmaceuticals, Inc. |
"Compounds and methods for inhibiting mitotic progression by inhibition of Aurora kinase"
|
ATE381566T1
(en)
*
|
2004-05-14 |
2008-01-15 |
Millennium Pharm Inc |
COMPOUNDS AND METHODS FOR INHIBITING MITOTIC PROGRESSION BY INHIBITING AURORAKINASE
|
KR20070012555A
(en)
*
|
2004-05-14 |
2007-01-25 |
버텍스 파마슈티칼스 인코포레이티드 |
Prodrugs of pyrrolylpyrimidine erk protein kinase inhibitors
|
PL1905773T3
(en)
*
|
2004-05-14 |
2012-12-31 |
Millennium Pharm Inc |
Compounds and methods for inhibiting mitotic progression by inhibition of aurora kinase
|
US20050255485A1
(en)
*
|
2004-05-14 |
2005-11-17 |
Livak Kenneth J |
Detection of gene duplications
|
JP2007538102A
(en)
*
|
2004-05-20 |
2007-12-27 |
バイエル・フアーマシユーチカルズ・コーポレーシヨン |
5-anilino-4-heteroarylpyrazole derivatives useful for the treatment of diabetes
|
CN1973247A
(en)
*
|
2004-05-27 |
2007-05-30 |
纳幕尔杜邦公司 |
Developer for a photopolymer protective layer
|
CA2571178A1
(en)
*
|
2004-07-01 |
2006-01-19 |
Synta Pharmaceuticals Corp. |
2-substituted heteroaryl compounds
|
EP1768964A1
(en)
*
|
2004-07-06 |
2007-04-04 |
Angion Biomedica Corporation |
Quinazoline modulators of hepatocyte growth factor / c-met activity for the treatment of cancer
|
EP1778669A2
(en)
*
|
2004-08-18 |
2007-05-02 |
Takeda San Diego, Inc. |
Kinase inhibitors
|
US7285569B2
(en)
|
2004-09-24 |
2007-10-23 |
Hoff Hoffmann-La Roche Inc. |
Tricycles, their manufacture and use as pharmaceutical agents
|
AR050948A1
(en)
|
2004-09-24 |
2006-12-06 |
Hoffmann La Roche |
DERIVATIVES OF FTALAZINONA; ITS OBTAINING AND ITS USE IN THE MANUFACTURE OF MEDICINES FOR THE TREATMENT OF CANCER.
|
EP1797048B1
(en)
*
|
2004-09-30 |
2011-08-17 |
Tibotec Pharmaceuticals |
Hiv inhibiting 5-carbo- or heterocyclic substituted pyrimidines
|
KR20070057899A
(en)
*
|
2004-09-30 |
2007-06-07 |
티보텍 파마슈티칼즈 리미티드 |
Hiv inhibiting 5-heterocyclyl pyrimidines
|
ATE542802T1
(en)
*
|
2004-09-30 |
2012-02-15 |
Tibotec Pharm Ltd |
HIV-INHIBITING 5-SUBSTITUTED PYRIMIDINES
|
US7713973B2
(en)
|
2004-10-15 |
2010-05-11 |
Takeda Pharmaceutical Company Limited |
Kinase inhibitors
|
JP4973190B2
(en)
*
|
2004-10-29 |
2012-07-11 |
Msd株式会社 |
Novel aminopyridine derivatives having selective inhibition of Aurora A
|
US7491720B2
(en)
*
|
2004-10-29 |
2009-02-17 |
Banyu Pharmaceutical Co., Ltd. |
Aminopyridine derivatives having Aurora A selective inhibitory action
|
JP2008519034A
(en)
|
2004-11-03 |
2008-06-05 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
Pyrimidine derivatives as ion channel modulators and methods of use
|
CN101084214A
(en)
*
|
2004-11-17 |
2007-12-05 |
迈卡纳治疗股份有限公司 |
Kinase inhibitors
|
JP5095409B2
(en)
|
2004-11-24 |
2012-12-12 |
ライジェル ファーマシューティカルズ, インコーポレイテッド |
Spiro 2,4-pyrimidinediamine compounds and uses thereof
|
US20060128710A1
(en)
*
|
2004-12-09 |
2006-06-15 |
Chih-Hung Lee |
Antagonists to the vanilloid receptor subtype 1 (VR1) and uses thereof
|
WO2006067614A2
(en)
*
|
2004-12-23 |
2006-06-29 |
Pfizer Products Inc. |
Heteroaromatic derivatives useful as anticancer agents
|
WO2006074057A2
(en)
|
2004-12-30 |
2006-07-13 |
Exelixis, Inc. |
Pyrimidine derivatives as kinase modulators and method of use
|
RU2416610C2
(en)
|
2004-12-30 |
2011-04-20 |
Астекс Терапьютикс Лимитед |
Pharmaceutical compounds
|
US8258145B2
(en)
|
2005-01-03 |
2012-09-04 |
Myrexis, Inc. |
Method of treating brain cancer
|
CA2592900A1
(en)
|
2005-01-03 |
2006-07-13 |
Myriad Genetics Inc. |
Nitrogen containing bicyclic compounds and therapeutical use thereof
|
MX2007007189A
(en)
|
2005-01-19 |
2010-09-28 |
Rigel Pharmaceuticals Inc |
Prodrugs of 2,4-pyrimidinediamine compounds and their uses.
|
US8404718B2
(en)
|
2005-01-21 |
2013-03-26 |
Astex Therapeutics Limited |
Combinations of pyrazole kinase inhibitors
|
AR054425A1
(en)
|
2005-01-21 |
2007-06-27 |
Astex Therapeutics Ltd |
PIPERIDIN ADDITION SALTS 4-IL-ACID AMID 4- (2,6-DICLORO-BENZOILAMINO) 1H-PIRAZOL-3-CARBOXILICO.
|
CA2595514C
(en)
*
|
2005-01-26 |
2012-06-12 |
Schering Corporation |
Kinase inhibitors
|
ME02645B
(en)
|
2005-02-04 |
2012-04-30 |
Astrazeneca Ab |
Pyrazolylaminopyridine derivatives useful as kinase inhibitors
|
PL1853588T3
(en)
*
|
2005-02-16 |
2008-11-28 |
Astrazeneca Ab |
Chemical compounds
|
DE602006015431D1
(en)
*
|
2005-02-16 |
2010-08-26 |
Astrazeneca Ab |
CHEMICAL COMPOUNDS
|
CN101500574A
(en)
*
|
2005-03-15 |
2009-08-05 |
Irm责任有限公司 |
Compounds and compositions as protein kinase inhbitors
|
EP1863797A1
(en)
*
|
2005-03-23 |
2007-12-12 |
AstraZeneca AB |
2-AZETIDINYL-4-(lH-PYRAZOL-3-YLAMINO)PYRIMIDINES AS INHIBITORS OF INSULIN-LIKE GROWTH FACTOR-I RECEPTOR ACTIVITY
|
US7297700B2
(en)
*
|
2005-03-24 |
2007-11-20 |
Renovis, Inc. |
Bicycloheteroaryl compounds as P2X7 modulators and uses thereof
|
KR20070116994A
(en)
*
|
2005-04-05 |
2007-12-11 |
아스트라제네카 아베 |
Pyrimidine derivatives for use as anticancer agents
|
GB0507347D0
(en)
*
|
2005-04-12 |
2005-05-18 |
Astrazeneca Ab |
Chemical compounds
|
CA2603204A1
(en)
|
2005-04-14 |
2006-10-19 |
F. Hoffmann-La Roche Ag |
Aminopyrazole derivatives, their manufacture and use as pharmaceutical agents
|
CN101208093A
(en)
*
|
2005-04-27 |
2008-06-25 |
阿斯利康(瑞典)有限公司 |
Use of pyrazolyl-pyrimidine derivatives in the treatment of pain
|
AU2006241825A1
(en)
*
|
2005-04-28 |
2006-11-09 |
Mitsubishi Tanabe Pharma Corporation |
Cyanopyridine derivative and use thereof as medicine
|
US20080207594A1
(en)
|
2005-05-04 |
2008-08-28 |
Davelogen Aktiengesellschaft |
Use of Gsk-3 Inhibitors for Preventing and Treating Pancreatic Autoimmune Disorders
|
JP5198256B2
(en)
|
2005-05-04 |
2013-05-15 |
エボテク エージー |
Fused heterocyclic compounds, and compositions and uses thereof
|
EP1888561A1
(en)
*
|
2005-05-05 |
2008-02-20 |
AstraZeneca AB |
Pyrazolyl-amino- substituted pyrimidines and their use in the treatment of cancer
|
NZ564317A
(en)
*
|
2005-05-16 |
2011-01-28 |
Astrazeneca Ab |
Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors
|
KR101312225B1
(en)
|
2005-06-08 |
2013-09-26 |
리겔 파마슈티칼스, 인크. |
Compositions and methods for inhibition of the jak pathway
|
US20070203161A1
(en)
|
2006-02-24 |
2007-08-30 |
Rigel Pharmaceuticals, Inc. |
Compositions and methods for inhibition of the jak pathway
|
EP1890703B1
(en)
|
2005-06-14 |
2016-05-11 |
Taigen Biotechnology |
Pyrimidine compounds as chemokine receptors inhibitors
|
US8193206B2
(en)
|
2005-06-14 |
2012-06-05 |
Taigen Biotechnology Co., Ltd. |
Pyrimidine compounds
|
EP1746096A1
(en)
|
2005-07-15 |
2007-01-24 |
4Sc Ag |
2-Arylbenzothiazole analogues and uses thereof in the treatment of cancer
|
AU2006279376B2
(en)
*
|
2005-08-18 |
2011-04-14 |
Vertex Pharmaceuticals Incoporated |
Pyrazine kinase inhibitors
|
WO2007023382A2
(en)
*
|
2005-08-25 |
2007-03-01 |
Pfizer Inc. |
Pyrimidine amino pyrazole compounds, potent kinase inhibitors
|
EP2258357A3
(en)
|
2005-08-26 |
2011-04-06 |
Braincells, Inc. |
Neurogenesis with acetylcholinesterase inhibitor
|
CA2620333A1
(en)
|
2005-08-26 |
2007-03-01 |
Braincells, Inc. |
Neurogenesis by muscarinic receptor modulation
|
CA2622352C
(en)
*
|
2005-09-30 |
2014-05-27 |
Miikana Therapeutics, Inc. |
Substituted pyrazole compounds
|
CN101316587B
(en)
*
|
2005-09-30 |
2013-04-03 |
迈卡纳治疗股份有限公司 |
Substituted pyrazole compounds
|
US8119655B2
(en)
|
2005-10-07 |
2012-02-21 |
Takeda Pharmaceutical Company Limited |
Kinase inhibitors
|
US7985756B2
(en)
|
2005-10-21 |
2011-07-26 |
Braincells Inc. |
Modulation of neurogenesis by PDE inhibition
|
DK1945631T3
(en)
*
|
2005-10-28 |
2012-10-22 |
Astrazeneca Ab |
4- (3-AMINOPYRAZOLE) PYRIMIDINE DERIVATIVES USED AS TYROSINKINASE INHIBITORS FOR CANCER TREATMENT
|
US20070112017A1
(en)
|
2005-10-31 |
2007-05-17 |
Braincells, Inc. |
Gaba receptor mediated modulation of neurogenesis
|
ES2372540T3
(en)
*
|
2005-11-01 |
2012-01-23 |
Array Biopharma, Inc. |
GLUCOCINASE ACTIVATORS.
|
NZ594385A
(en)
*
|
2005-11-03 |
2013-02-22 |
Vertex Pharma |
Aminopyrimidines useful as kinase inhibitors
|
EP1951716B1
(en)
*
|
2005-11-16 |
2011-05-04 |
Vertex Pharmaceuticals, Inc. |
Aminopyrimidines useful as kinase inhibitors
|
US8546404B2
(en)
*
|
2005-12-13 |
2013-10-01 |
Merck Sharp & Dohme |
Compounds that are ERK inhibitors
|
US7572809B2
(en)
*
|
2005-12-19 |
2009-08-11 |
Hoffmann-La Roche Inc. |
Isoquinoline aminopyrazole derivatives
|
WO2007077435A1
(en)
|
2005-12-30 |
2007-07-12 |
Astex Therapeutics Limited |
Pharmaceutical compounds
|
WO2007081978A2
(en)
*
|
2006-01-11 |
2007-07-19 |
Angion Biomedica Corporation |
Modulators of hepatocyte growth factor / c-met activity
|
JO2660B1
(en)
|
2006-01-20 |
2012-06-17 |
نوفارتيس ايه جي |
PI-3 Kinase inhibitors and methods of their use
|
JP2009528280A
(en)
|
2006-02-16 |
2009-08-06 |
シェーリング コーポレイション |
Pyrrolidine derivatives as ERK inhibitors
|
US20100216734A1
(en)
|
2006-03-08 |
2010-08-26 |
Braincells, Inc. |
Modulation of neurogenesis by nootropic agents
|
PE20080145A1
(en)
|
2006-03-21 |
2008-02-11 |
Janssen Pharmaceutica Nv |
TETRAHYDRO-PYRIMIDOAZEPINE AS MODULATORS OF TRPV1
|
AU2007233737B2
(en)
|
2006-03-30 |
2012-11-29 |
Janssen Sciences Ireland Uc |
HIV inhibiting 5-amido substituted pyrimidines
|
JP5255559B2
(en)
*
|
2006-03-31 |
2013-08-07 |
アボット・ラボラトリーズ |
Indazole compound
|
KR20090023561A
(en)
|
2006-04-07 |
2009-03-05 |
노파르티스 아게 |
Combination comprising a) a pyrimidylaminobenzamide compound, and b) a thr315ile kinase inhibitor
|
JP5290147B2
(en)
|
2006-04-14 |
2013-09-18 |
プラナ バイオテクノロジー リミティッド |
Method for treating age-related macular degeneration (AMD)
|
JP5161072B2
(en)
*
|
2006-04-27 |
2013-03-13 |
Msd株式会社 |
Novel aminopyridine derivatives having selective inhibition of Aurora A
|
JP2009536669A
(en)
|
2006-05-09 |
2009-10-15 |
ブレインセルス,インコーポレイティド |
Neurogenesis by angiotensin regulation
|
MX2008014320A
(en)
|
2006-05-09 |
2009-03-25 |
Braincells Inc |
5 ht receptor mediated neurogenesis.
|
GEP20115359B
(en)
|
2006-06-27 |
2011-12-26 |
Takeda Pharmaceutical |
Fused cyclic compounds
|
JP5523829B2
(en)
|
2006-06-29 |
2014-06-18 |
アステックス、セラピューティックス、リミテッド |
Compound drug
|
EP2043635A2
(en)
*
|
2006-06-29 |
2009-04-08 |
Astex Therapeutics Limited |
Pharmaceutical combinations
|
EP2044063A1
(en)
*
|
2006-06-30 |
2009-04-08 |
Astra Zeneca AB |
Pyrimidine derivatives useful in the treatment of cancer
|
US20090209537A1
(en)
*
|
2006-06-30 |
2009-08-20 |
Kyowa Hakko Kirin Co., Ltd. |
Aurora inhibitors
|
EP2043651A2
(en)
|
2006-07-05 |
2009-04-08 |
Exelixis, Inc. |
Methods of using igf1r and abl kinase modulators
|
KR20090047458A
(en)
|
2006-08-08 |
2009-05-12 |
사노피-아벤티스 |
Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, processes for preparing them, medicaments comprising these compounds, and their use
|
US7718648B2
(en)
*
|
2006-08-09 |
2010-05-18 |
Millennium Pharmaceuticals, Inc. |
Pyridobenzazepine compounds and methods for inhibiting mitotic progression
|
US7744164B2
(en)
*
|
2006-08-11 |
2010-06-29 |
Schluimberger Technology Corporation |
Shield of a degradation assembly
|
JP2008081492A
(en)
*
|
2006-08-31 |
2008-04-10 |
Banyu Pharmaceut Co Ltd |
New aminopyridine derivative having aurora a selective inhibitory action
|
AU2007292848A1
(en)
*
|
2006-09-08 |
2008-03-13 |
Braincells, Inc. |
Combinations containing a 4-acylaminopyridine derivative
|
US20100184806A1
(en)
|
2006-09-19 |
2010-07-22 |
Braincells, Inc. |
Modulation of neurogenesis by ppar agents
|
EP2223925A1
(en)
*
|
2006-10-09 |
2010-09-01 |
Takeda Pharmaceutical Company Limited |
Kinase inhibitors
|
EA200970361A1
(en)
|
2006-10-09 |
2010-02-26 |
Такеда Фармасьютикал Компани Лимитед |
KINASE INHIBITORS
|
WO2008044041A1
(en)
|
2006-10-12 |
2008-04-17 |
Astex Therapeutics Limited |
Pharmaceutical combinations
|
JP5528807B2
(en)
|
2006-10-12 |
2014-06-25 |
アステックス、セラピューティックス、リミテッド |
Compound drug
|
WO2008053812A1
(en)
*
|
2006-10-27 |
2008-05-08 |
Mitsubishi Tanabe Pharma Corporation |
Cyanopyridine derivative and medicinal use thereof
|
MX2009004807A
(en)
*
|
2006-11-02 |
2009-06-15 |
Vertex Pharma |
Aminopyridines and aminopyrimidines useful as inhibitors of protein kinases.
|
CL2007003244A1
(en)
|
2006-11-16 |
2008-04-04 |
Millennium Pharm Inc |
COMPOUNDS DERIVED FROM PIRIMIDO [5,4-D] [2] BENZAZEPINA; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUND; AND USE OF THE COMPOUND FOR THE TREATMENT OF CANCER.
|
DE602007007985D1
(en)
*
|
2006-12-19 |
2010-09-02 |
Vertex Pharma |
AS INHIBITORS OF PROTEIN KINASES SUITABLE AMINO-PRIMIDINES
|
CN101573343B
(en)
*
|
2006-12-29 |
2016-02-24 |
爱尔兰詹森科学公司 |
The pyrimidine of the 6-replacement of HIV inhibiting
|
EA020749B1
(en)
*
|
2006-12-29 |
2015-01-30 |
Тиботек Фармасьютикалз Лтд. |
Hiv inhibiting 5,6-substituted pyrimidines
|
KR20090108124A
(en)
|
2007-02-06 |
2009-10-14 |
노파르티스 아게 |
Pi 3-kinase inhibitors and methods of their use
|
US20100104567A1
(en)
|
2007-03-05 |
2010-04-29 |
Kyowa Hakko Kirin Co., Ltd. |
Pharmaceutical composition
|
AU2008226466B2
(en)
*
|
2007-03-09 |
2013-06-13 |
Vertex Pharmaceuticals Incorporated |
Aminopyrimidines useful as inhibitors of protein kinases
|
JP5520057B2
(en)
*
|
2007-03-09 |
2014-06-11 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
Aminopyrimidines useful as inhibitors of protein kinases
|
EP2134709A1
(en)
|
2007-03-09 |
2009-12-23 |
Vertex Pharmaceuticals, Inc. |
Aminopyridines useful as inhibitors of protein kinases
|
AU2008228963A1
(en)
*
|
2007-03-20 |
2008-09-25 |
Vertex Pharmaceuticals Incorporated |
Aminopyrimidines useful as kinase inhibitors
|
WO2008117050A1
(en)
*
|
2007-03-27 |
2008-10-02 |
Astrazeneca Ab |
Pyrazolyl-amino-substituted pyrazines and their use for the treatment of cancer
|
CN101679386A
(en)
*
|
2007-04-13 |
2010-03-24 |
沃泰克斯药物股份有限公司 |
Aminopyrimidines useful as kinase inhibitors
|
GEP20125581B
(en)
|
2007-04-18 |
2012-07-25 |
Pfizer Prod Inc |
Sulfonyl amide derivatives for treatment of abnormal cell growth
|
WO2008129255A1
(en)
*
|
2007-04-18 |
2008-10-30 |
Astrazeneca Ab |
5-aminopyrazol-3-yl-3h-imidazo [4,5-b] pyridine derivatives and their use for the treatment of cancer
|
AU2008247594A1
(en)
*
|
2007-05-02 |
2008-11-13 |
Vertex Pharmaceuticals Incorporated |
Aminopyrimidines useful as kinase inhibitors
|
JP5572087B2
(en)
*
|
2007-05-02 |
2014-08-13 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
Aminopyrimidines useful as kinase inhibitors
|
EP2152694A2
(en)
|
2007-05-02 |
2010-02-17 |
Vertex Pharmaceuticals Incorporated |
Thiazoles and pyrazoles useful as kinase inhibitors
|
ES2369596T3
(en)
*
|
2007-05-04 |
2011-12-02 |
Astrazeneca Ab |
DERIVATIVES OF AMINO-TIAZOLIL-PYRIMIDINE AND ITS USE FOR THE TREATMENT OF CANCER.
|
UA99459C2
(en)
|
2007-05-04 |
2012-08-27 |
Астразенека Аб |
9-(pyrazol-3-yl)- 9h-purine-2-amine and 3-(pyraz0l-3-yl)-3h-imidazo[4,5-b]pyridin-5-amine derivatives and their use for the treatment of cancer
|
AU2008257044A1
(en)
*
|
2007-05-24 |
2008-12-04 |
Vertex Pharmaceuticals Incorporated |
Thiazoles and pyrazoles useful as kinase inhibitors
|
KR101294731B1
(en)
*
|
2007-06-04 |
2013-08-16 |
삼성디스플레이 주식회사 |
Array substrate, display panel having the array substrate and method of manufacturing the array substrate
|
JP2010529193A
(en)
*
|
2007-06-11 |
2010-08-26 |
ミイカナ セラピューティクス インコーポレイテッド |
Substituted pyrazole compounds
|
US20090274698A1
(en)
*
|
2007-07-06 |
2009-11-05 |
Shripad Bhagwat |
Combination anti-cancer therapy
|
WO2009007753A2
(en)
*
|
2007-07-11 |
2009-01-15 |
Astrazeneca Ab |
4- (3-aminopyrazole) -pyrimidine derivativee and their use as tyrosine kinase inhibitors for the treatment of cancer
|
EP2175933B1
(en)
*
|
2007-07-25 |
2012-08-22 |
Bristol-Myers Squibb Company |
Triazine kinase inhibitors
|
WO2009013545A2
(en)
*
|
2007-07-26 |
2009-01-29 |
Astrazeneca Ab |
Chemical compounds
|
TW200906818A
(en)
*
|
2007-07-31 |
2009-02-16 |
Astrazeneca Ab |
Chemical compounds
|
EP2176261B1
(en)
*
|
2007-07-31 |
2012-12-19 |
Vertex Pharmaceuticals Incorporated |
Process for preparing 5-fluoro-1h-pyrazolo [3, 4-b] pyridin-3-amine and derivatives thereof
|
EP2025674A1
(en)
|
2007-08-15 |
2009-02-18 |
sanofi-aventis |
Substituted tetra hydro naphthalines, method for their manufacture and their use as drugs
|
WO2009027736A2
(en)
*
|
2007-08-27 |
2009-03-05 |
Astrazeneca Ab |
2,4 diaminopyrimid'lnes for the treatment of myeloproliferative disorders and cancer
|
CN101868459B
(en)
|
2007-09-21 |
2013-12-18 |
阿雷生物药品公司 |
Pyridin-2 -yl-amino-1, 2, 4 -thiadiazole derivatives as glucokinase activators for treatment of diabetes mellitus
|
MX2010003942A
(en)
|
2007-10-11 |
2010-04-30 |
Glaxosmithkline Llc |
Novel seh inhibitors and their use.
|
WO2009078999A1
(en)
|
2007-12-17 |
2009-06-25 |
Janssen Pharmaceutica N.V. |
Imidazolo-, oxazolo-, and thiazolopyrimidine modulators of trpv1
|
US20090270418A1
(en)
*
|
2008-01-09 |
2009-10-29 |
Marianne Sloss |
Pyrazole pyrazine amine compounds as kinase inhibitors, compositions thereof and methods of treatment therewith
|
EP2242745A1
(en)
*
|
2008-02-07 |
2010-10-27 |
Sanofi-Aventis |
Novel phenyl-substituted imidazolidines, method for the production thereof, medicaments containing said compounds and use thereof
|
CA2714479A1
(en)
*
|
2008-02-21 |
2009-08-27 |
Schering Corporation |
Compounds that are erk inhibitors
|
AU2009216062B2
(en)
*
|
2008-02-22 |
2013-02-07 |
Msd K.K. |
Novel aminopyridine derivatives having Aurora A selective inhibitory action
|
EP2268635B1
(en)
|
2008-04-21 |
2015-06-10 |
Taigen Biotechnology Co., Ltd. |
Heterocyclic compounds
|
US8844033B2
(en)
|
2008-05-27 |
2014-09-23 |
The Trustees Of Columbia University In The City Of New York |
Systems, methods, and media for detecting network anomalies using a trained probabilistic model
|
EP2288602A1
(en)
*
|
2008-06-11 |
2011-03-02 |
AstraZeneca AB |
Tricyclic 2,4-diamin0-l,3,5-triazine derivatives useful for the treatment of cancer and myeloproliferative disorders
|
US8470841B2
(en)
|
2008-07-09 |
2013-06-25 |
Sanofi |
Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
|
AU2009276339B2
(en)
*
|
2008-07-31 |
2012-06-07 |
Genentech, Inc. |
Pyrimidine compounds, compositions and methods of use
|
JP2012501971A
(en)
*
|
2008-09-03 |
2012-01-26 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
Co-crystals and pharmaceutical formulations containing co-crystals
|
NZ621143A
(en)
*
|
2008-09-05 |
2016-08-26 |
Celgene Avilomics Res Inc |
Algorithm for designing irreversible inhibitors
|
CA2737388C
(en)
*
|
2008-09-15 |
2017-07-11 |
Peter Walter |
Methods and compositions for modulating ire1, src, and abl activity
|
KR20110071098A
(en)
*
|
2008-09-30 |
2011-06-28 |
아스트라제네카 아베 |
Heterocyclic jak kinase inhibitors
|
US8759362B2
(en)
*
|
2008-10-24 |
2014-06-24 |
Purdue Pharma L.P. |
Bicycloheteroaryl compounds and their use as TRPV1 ligands
|
WO2010056758A1
(en)
*
|
2008-11-12 |
2010-05-20 |
Yangbo Feng |
Quinazoline derivatives as kinase inhibitors
|
WO2010056847A2
(en)
|
2008-11-13 |
2010-05-20 |
Taigen Biotechnology Co., Ltd. |
Lyophilization formulation
|
WO2010068601A1
(en)
|
2008-12-08 |
2010-06-17 |
Sanofi-Aventis |
A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
|
PA8851101A1
(en)
|
2008-12-16 |
2010-07-27 |
Lilly Co Eli |
AMINO PIRAZOL COMPOUND
|
JP5490137B2
(en)
*
|
2008-12-19 |
2014-05-14 |
ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ |
Bicyclic pyrazoles as protein kinase inhibitors
|
CN102264368B
(en)
|
2008-12-22 |
2014-09-10 |
米伦纽姆医药公司 |
Combination of aurora kinase inhibitors and anti-CD20 antibodies
|
WO2010072155A1
(en)
*
|
2008-12-26 |
2010-07-01 |
复旦大学 |
Pyrimidine derivative, preparation method and use thereof
|
US20100216805A1
(en)
|
2009-02-25 |
2010-08-26 |
Braincells, Inc. |
Modulation of neurogenesis using d-cycloserine combinations
|
SI2401267T1
(en)
|
2009-02-27 |
2014-05-30 |
Ambit Biosciences Corporation |
Jak kinase modulating quinazoline derivatives and their use in methods
|
CA2660962A1
(en)
|
2009-03-31 |
2010-09-30 |
Astellas Pharma Inc. |
Novel pharmaceutical composition for treatment of schizophrenia
|
US8399663B2
(en)
|
2009-04-03 |
2013-03-19 |
Astellas Pharma Inc. |
Salt of 1,3,5-triazine-2,4,6-triamine derivative
|
JO3635B1
(en)
|
2009-05-18 |
2020-08-27 |
Millennium Pharm Inc |
Solid pharmaceutical compositions and processes for their production
|
JP2012529511A
(en)
*
|
2009-06-08 |
2012-11-22 |
アブラクシス バイオサイエンス リミテッド ライアビリティー カンパニー |
Triazine derivatives and their therapeutic applications
|
US20120172361A1
(en)
*
|
2009-06-08 |
2012-07-05 |
California Capital Equity, Llc |
Triazine derivatives and their therapeutical applications
|
KR20120016676A
(en)
*
|
2009-06-09 |
2012-02-24 |
아브락시스 바이오사이언스, 엘엘씨 |
Ureidophenyl substituted triazine derivatives and their therapeutical applications
|
JP5785940B2
(en)
*
|
2009-06-09 |
2015-09-30 |
アブラクシス バイオサイエンス, エルエルシー |
Triazine derivatives and their therapeutic applications
|
EP2440053A4
(en)
*
|
2009-06-09 |
2012-10-31 |
California Capital Equity Llc |
Benzyl substituted triazine derivatives and their therapeutical applications
|
WO2010144423A1
(en)
*
|
2009-06-09 |
2010-12-16 |
Abraxis Bioscience, Llc |
Styryl-triazine derivatives and their therapeutical applications
|
CA2763730A1
(en)
*
|
2009-06-18 |
2010-12-23 |
Cellzome Limited |
Heterocyclylaminopyrimidines as kinase inhibitors
|
US8637525B2
(en)
|
2009-07-31 |
2014-01-28 |
Bristol-Myers Squibb Company |
Compounds for the reduction of beta-amyloid production
|
TWI468402B
(en)
*
|
2009-07-31 |
2015-01-11 |
必治妥美雅史谷比公司 |
Compounds for the reduction of β-amyloid production
|
RU2012111354A
(en)
|
2009-08-26 |
2013-10-10 |
Санофи |
NEW CRYSTALLINE HYDRATES OF FLUORGYCLOSIDES CONTAINING THEIR PHARMACEUTICAL DRUGS AND THEIR USE
|
NZ598705A
(en)
|
2009-09-16 |
2014-06-27 |
Celgene Avilomics Res Inc |
Protein kinase conjugates and inhibitors
|
EP3639783A1
(en)
*
|
2009-11-13 |
2020-04-22 |
Intuitive Surgical Operations, Inc. |
End effector with redundant closing mechanisms
|
AU2010343102B2
(en)
|
2009-12-29 |
2016-03-24 |
Dana-Farber Cancer Institute, Inc. |
Type II Raf kinase inhibitors
|
SG181965A1
(en)
|
2009-12-30 |
2012-08-30 |
Avila Therapeutics Inc |
Ligand-directed covalent modification of protein
|
SA111320200B1
(en)
*
|
2010-02-17 |
2014-02-16 |
ديبيوفارم اس ايه |
Bicyclic Compounds and their Uses as Dual C-SRC / JAK Inhibitors
|
JP2013520424A
(en)
|
2010-02-19 |
2013-06-06 |
ミレニアム ファーマシューティカルズ, インコーポレイテッド |
Sodium 4-{[9-chloro-7- (2-fluoro-6-methoxyphenyl) -5H-pyrimido [5,4-d] [2] benzoazepin-2-yl] amino} -2-methoxybenzoate Crystal form
|
WO2011107494A1
(en)
|
2010-03-03 |
2011-09-09 |
Sanofi |
Novel aromatic glycoside derivatives, medicaments containing said compounds, and the use thereof
|
WO2011146354A1
(en)
*
|
2010-05-20 |
2011-11-24 |
Merck Sharp & Dohme Corp. |
Novel prolylcarboxypeptidase inhibitors
|
CA2798578C
(en)
|
2010-05-21 |
2015-12-29 |
Chemilia Ab |
Novel pyrimidine derivatives
|
CN103038230B
(en)
|
2010-06-04 |
2016-05-25 |
霍夫曼-拉罗奇有限公司 |
As the aminopyridine derivative of LRRK2 conditioning agent
|
EP2582709B1
(en)
|
2010-06-18 |
2018-01-24 |
Sanofi |
Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
|
US8530413B2
(en)
|
2010-06-21 |
2013-09-10 |
Sanofi |
Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
|
TW201215388A
(en)
|
2010-07-05 |
2012-04-16 |
Sanofi Sa |
(2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
|
TW201215387A
(en)
|
2010-07-05 |
2012-04-16 |
Sanofi Aventis |
Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
|
TW201221505A
(en)
|
2010-07-05 |
2012-06-01 |
Sanofi Sa |
Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
|
US9181198B2
(en)
|
2010-07-29 |
2015-11-10 |
Oryzon Genomics S.A. |
Arylcyclopropylamine based demethylase inhibitors of LSD1 and their medical use
|
WO2012030944A2
(en)
*
|
2010-09-01 |
2012-03-08 |
Ambit Biosciences Corporation |
Quinoline and isoquinoline compounds and methods of use thereof
|
US20120053176A1
(en)
*
|
2010-09-01 |
2012-03-01 |
Ambit Biosciences Corp. |
Adenosine a3 receptor modulating compounds and methods of use thereof
|
EP2611793A1
(en)
*
|
2010-09-01 |
2013-07-10 |
Ambit Biosciences Corporation |
2-cycloquinazoline derivatives and methods of use thereof
|
WO2012030917A1
(en)
*
|
2010-09-01 |
2012-03-08 |
Ambit Biosciences Corporation |
An optically active pyrazolylaminoquinazoline, and pharmaceutical compositions and methods of use thereof
|
EP2611794A1
(en)
*
|
2010-09-01 |
2013-07-10 |
Ambit Biosciences Corporation |
4-azolylaminoquinazoline derivatives and methods of use thereof
|
CA2810024A1
(en)
|
2010-09-01 |
2012-03-08 |
Ambit Biosciences Corporation |
Quinazoline compounds and methods of use thereof
|
ES2619850T3
(en)
*
|
2010-09-01 |
2017-06-27 |
Ambit Biosciences Corporation |
Hydrobromide salts of a pyrazolilaminoquinazoline
|
WO2012059932A1
(en)
|
2010-11-01 |
2012-05-10 |
Aurigene Discovery Technologies Limited |
2, 4 -diaminopyrimidine derivatives as protein kinase inhibitors
|
NO2638031T3
(en)
|
2010-11-10 |
2018-03-10 |
|
|
WO2012120058A1
(en)
|
2011-03-08 |
2012-09-13 |
Sanofi |
Oxathiazine derivatives which are substituted with benzyl or heteromethylene groups, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
|
US8809325B2
(en)
|
2011-03-08 |
2014-08-19 |
Sanofi |
Benzyl-oxathiazine derivatives substituted with adamantane and noradamantane, medicaments containing said compounds and use thereof
|
WO2012120054A1
(en)
|
2011-03-08 |
2012-09-13 |
Sanofi |
Di- and tri-substituted oxathiazine derivates, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
|
WO2012120050A1
(en)
|
2011-03-08 |
2012-09-13 |
Sanofi |
Novel substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
|
WO2012120057A1
(en)
|
2011-03-08 |
2012-09-13 |
Sanofi |
Novel substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
|
US8828995B2
(en)
|
2011-03-08 |
2014-09-09 |
Sanofi |
Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
|
EP2683699B1
(en)
|
2011-03-08 |
2015-06-24 |
Sanofi |
Di- and tri-substituted oxathiazine derivates, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
|
US8901114B2
(en)
|
2011-03-08 |
2014-12-02 |
Sanofi |
Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof
|
WO2012120056A1
(en)
|
2011-03-08 |
2012-09-13 |
Sanofi |
Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
|
ES2587864T3
(en)
|
2011-03-24 |
2016-10-27 |
Noviga Research Ab |
Pyrimidine derivatives
|
US8637537B2
(en)
|
2011-08-25 |
2014-01-28 |
Genentech, Inc. |
Serine/threonine kinase inhibitors
|
WO2013037390A1
(en)
|
2011-09-12 |
2013-03-21 |
Sanofi |
6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
|
EA201490673A1
(en)
|
2011-09-22 |
2014-06-30 |
Пфайзер Инк. |
DERIVATIVES OF PYRROLOPYRIMIDINE AND PURIN
|
CU24269B1
(en)
|
2011-09-27 |
2017-08-08 |
Novartis Ag |
3- PIRIMIDIN- 4-IL- OXAZOLIDIN- 2- INHIBITING WAVES OF THE MUTANT HDI
|
WO2013045413A1
(en)
|
2011-09-27 |
2013-04-04 |
Sanofi |
6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
|
JP6106685B2
(en)
|
2011-11-17 |
2017-04-05 |
ダナ−ファーバー キャンサー インスティテュート, インコーポレイテッド |
Inhibitors of C-JUN-N-terminal kinase (JNK)
|
KR20140103972A
(en)
|
2011-12-22 |
2014-08-27 |
에프. 호프만-라 로슈 아게 |
2,4-diamine-pyrimidine derivatives as serine/threonine kinase inhibitors
|
CA2864825C
(en)
*
|
2012-02-17 |
2021-01-26 |
Abbvie Inc. |
Diaminopyrimidines useful as inhibitors of the human respiratory syncytial virus (rsv)
|
UY34632A
(en)
|
2012-02-24 |
2013-05-31 |
Novartis Ag |
OXAZOLIDIN- 2- ONA COMPOUNDS AND USES OF THE SAME
|
TWI485146B
(en)
*
|
2012-02-29 |
2015-05-21 |
Taiho Pharmaceutical Co Ltd |
Novel piperidine compounds or salts thereof
|
CN104302640A
(en)
|
2012-03-16 |
2015-01-21 |
埃克希金医药品有限公司 |
3,5-diaminopyrazole kinase inhibitors
|
US20130303519A1
(en)
|
2012-03-20 |
2013-11-14 |
Millennium Pharmaceuticals, Inc. |
Methods of treating cancer using aurora kinase inhibitors
|
DK3459942T3
(en)
|
2012-04-24 |
2021-03-08 |
Vertex Pharma |
DNA-PK inhibitors
|
JP6197031B2
(en)
*
|
2012-05-24 |
2017-09-13 |
セルゾーム リミティッド |
Heterocyclyl pyrimidine analogs as TYK2 inhibitors
|
JP6280546B2
(en)
|
2012-06-26 |
2018-02-14 |
デル マー ファーマシューティカルズ |
Treating tyrosine kinase inhibitor resistant malignancies in patients with genetic polymorphisms or dysregulation or mutation of AHI1 using dianhydrogalactitol, diacetyldianhydrogalactitol, dibromodulucitol, or analogs or derivatives thereof How to
|
US9216991B2
(en)
*
|
2012-07-10 |
2015-12-22 |
Ares Trading S.A. |
Pyrimidine pyrazolyl derivatives
|
BR112015005489B1
(en)
*
|
2012-09-19 |
2022-07-12 |
Taiho Pharmaceutical Co., Ltd. |
PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION WITH IMPROVED DISSOLUTION AND/OR ABSORPTION
|
US9296733B2
(en)
|
2012-11-12 |
2016-03-29 |
Novartis Ag |
Oxazolidin-2-one-pyrimidine derivative and use thereof for the treatment of conditions, diseases and disorders dependent upon PI3 kinases
|
CN103191120B
(en)
*
|
2012-12-31 |
2015-11-25 |
刘强 |
A kind of pyrimidine derivatives preparation prevent and/or treat and/or adjuvant therapy of tumors medicine in purposes
|
CN103059002B
(en)
*
|
2012-12-31 |
2015-04-22 |
中山大学 |
Pyrimidine derivative with Aurora kinase inhibitory activity and preparation method and application thereof
|
CN103202843B
(en)
*
|
2012-12-31 |
2015-04-29 |
刘强 |
Application of pyrimidine derivative in preparation of drugs capable of prevention and/or treatment and/or adjuvant therapy of cancers
|
CN103910716A
(en)
*
|
2013-01-07 |
2014-07-09 |
华东理工大学 |
2,4-disubstituted-cycloalkyl[d]pyrimidine compound and its use
|
EP3985003B1
(en)
|
2013-03-12 |
2023-08-09 |
Vertex Pharmaceuticals Incorporated |
Dna-pk inhibitors
|
EA028033B1
(en)
|
2013-03-14 |
2017-09-29 |
Новартис Аг |
3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh
|
EP3842424A1
(en)
|
2013-03-15 |
2021-06-30 |
The Trustees of Columbia University in the City of New York |
Map kinase modulators and uses thereof in the tretament of tauopathies
|
JP6360881B2
(en)
|
2013-03-22 |
2018-07-18 |
ミレニアム ファーマシューティカルズ, インコーポレイテッドMillennium Pharmaceuticals, Inc. |
Combination of catalytic MTORC1 / 2 inhibitor and selective inhibitor of Aurora A kinase
|
WO2015003355A2
(en)
*
|
2013-07-11 |
2015-01-15 |
Agios Pharmaceuticals, Inc. |
Therapeutically active compounds and their methods of use
|
CN105764502A
(en)
|
2013-07-26 |
2016-07-13 |
现代化制药公司 |
Combinatorial methods to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof
|
WO2015028848A1
(en)
*
|
2013-09-02 |
2015-03-05 |
Piramal Enterprises Limited |
Bicyclic heterocyclic compounds as multi-kinase inhibitors
|
NZ631142A
(en)
|
2013-09-18 |
2016-03-31 |
Axikin Pharmaceuticals Inc |
Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors
|
SI3424920T1
(en)
|
2013-10-17 |
2020-08-31 |
Vertex Pharmaceuticals Incorporated |
Co-crystals of (s)-n-methyl-8-(1-((2'-methyl-(4,5'-bipyrimidin)-6-yl)amino)propan-2-yl)quinoline-4-carboxamide and deuterated derivatives thereof as dna-pk inhibitors
|
AU2014337044A1
(en)
|
2013-10-18 |
2016-05-05 |
Dana-Farber Cancer Institute, Inc. |
Polycyclic inhibitors of cyclin-dependent kinase 7 (CDK7)
|
US20160264551A1
(en)
|
2013-10-18 |
2016-09-15 |
Syros Pharmaceuticals, Inc. |
Heteroaromatic compounds useful for the treatment of prolferative diseases
|
HUE050761T2
(en)
|
2014-01-01 |
2021-01-28 |
Medivation Tech Llc |
Compounds and methods of use
|
PT3116475T
(en)
|
2014-03-13 |
2020-12-15 |
Neuroderm Ltd |
Dopa decarboxylase inhibitor compositions
|
US10258585B2
(en)
|
2014-03-13 |
2019-04-16 |
Neuroderm, Ltd. |
DOPA decarboxylase inhibitor compositions
|
JP6538148B2
(en)
|
2014-03-28 |
2019-07-03 |
キャリター・サイエンシーズ・リミテッド・ライアビリティ・カンパニーCalitor Sciences, Llc |
Substituted heteroaryl compounds and methods of use
|
CA2944240A1
(en)
|
2014-04-04 |
2015-10-08 |
Iomet Pharma Ltd |
Indole derivatives as ido/tdo inhibitors
|
WO2015155738A2
(en)
|
2014-04-09 |
2015-10-15 |
Christopher Rudd |
Use of gsk-3 inhibitors or activators which modulate pd-1 or t-bet expression to modulate t cell immunity
|
CN105367555B
(en)
*
|
2014-08-07 |
2019-06-25 |
广东东阳光药业有限公司 |
Substituted heteroaryl compound and combinations thereof and purposes
|
JP6450010B2
(en)
|
2014-12-23 |
2019-01-09 |
アクシキン ファーマシューティカルズ インコーポレーテッド |
3,5-diaminopyrazole kinase inhibitor
|
CA2972239A1
(en)
|
2014-12-23 |
2016-06-30 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of cyclin-dependent kinase 7 (cdk7)
|
US10227343B2
(en)
*
|
2015-01-30 |
2019-03-12 |
Vanderbilt University |
Isoquiniline and napthalene-substituted compounds as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction
|
CA2978518C
(en)
|
2015-03-27 |
2023-11-21 |
Nathanael S. Gray |
Inhibitors of cyclin-dependent kinases
|
CA2982890C
(en)
|
2015-04-17 |
2023-08-22 |
Ludwig Institute For Cancer Research Ltd |
Plk4 inhibitors
|
SG10201910742VA
(en)
|
2015-05-28 |
2020-01-30 |
Theravance Biopharma R&D Ip Llc |
Naphthyridine compounds as jak kinase inhibitors
|
JP2018135268A
(en)
*
|
2015-06-05 |
2018-08-30 |
大日本住友製薬株式会社 |
Novel heteroaryl amino-3-pyrazole derivative and pharmacologically acceptable salt thereof
|
EP3324976A4
(en)
|
2015-07-21 |
2019-03-27 |
Millennium Pharmaceuticals, Inc. |
Administration of aurora kinase inhibitor and chemotherapeutic agents
|
CA2996978A1
(en)
|
2015-09-09 |
2017-03-16 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of cyclin-dependent kinases
|
EP3347097B1
(en)
|
2015-09-11 |
2021-02-24 |
Sunshine Lake Pharma Co., Ltd. |
Substituted aminopyrimidine derivatives as modulators of the kinases jak, flt3 and aurora
|
KR102488323B1
(en)
*
|
2015-12-10 |
2023-01-12 |
피티씨 테라퓨틱스, 인크. |
Composition for treating or ameliorating Huntington's disease
|
CN105399695B
(en)
*
|
2015-12-11 |
2019-04-19 |
浙江大学 |
Compound in triazine class and its preparation method and application
|
CN105384702B
(en)
*
|
2015-12-11 |
2018-04-10 |
浙江大学 |
Three substitution s-triazine compounds and preparation method thereof
|
CN105503754B
(en)
*
|
2015-12-11 |
2017-11-17 |
浙江大学 |
The triazine of 2 amino, 4 benzyl, 6 morpholine 1,3,5 and its preparation and application
|
WO2017102091A1
(en)
|
2015-12-18 |
2017-06-22 |
Bayer Pharma Aktiengesellschaft |
Heteroarylbenzimidazole compounds
|
US10822311B2
(en)
|
2016-03-14 |
2020-11-03 |
Afferent Pharmaceuticals, Inc. |
Pyrimidines and variants thereof, and uses therefor
|
JP6902045B2
(en)
|
2016-03-25 |
2021-07-14 |
アファレント ファーマシューティカルズ インコーポレイテッド |
Pyrimidines and their variants, and their use
|
SG11201809342YA
(en)
|
2016-04-28 |
2018-11-29 |
Theravance Biopharma R&D Ip Llc |
Pyrimidine compounds as jak kinase inhibitors
|
WO2017207534A1
(en)
|
2016-06-03 |
2017-12-07 |
Bayer Pharma Aktiengesellschaft |
Substituted heteroarylbenzimidazole compounds
|
MX2019003317A
(en)
|
2016-09-27 |
2019-08-05 |
Vertex Pharma |
Method for treating cancer using a combination of dna-damaging agents and dna-pk inhibitors.
|
US10858319B2
(en)
|
2016-10-03 |
2020-12-08 |
Iomet Pharma Ltd. |
Indole derivatives for use in medicine
|
US10968227B2
(en)
*
|
2016-11-08 |
2021-04-06 |
Vanderbilt University |
Isoquinoline ether compounds as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction
|
CN108239071B
(en)
*
|
2016-12-27 |
2020-12-04 |
沈阳药科大学 |
Amide and thioamide derivatives, and preparation method and application thereof
|
FR3064275B1
(en)
|
2017-03-21 |
2019-06-07 |
Arkema France |
METHOD FOR HEATING AND / OR AIR CONDITIONING A VEHICLE
|
IL270873B2
(en)
|
2017-05-30 |
2023-04-01 |
Basf Se |
“derivatives of pyridine and pyrazine compounds, composition comprising them and their use as fungicides”
|
SG11201911615WA
(en)
|
2017-06-05 |
2020-01-30 |
Ptc Therapeutics Inc |
Compounds for treating huntington's disease
|
CA3067591A1
(en)
|
2017-06-28 |
2019-01-03 |
Ptc Therapeutics, Inc. |
Methods for treating huntington's disease
|
CA3067592A1
(en)
|
2017-06-28 |
2019-01-03 |
Ptc Therapeutics, Inc. |
Methods for treating huntington's disease
|
WO2019001572A1
(en)
|
2017-06-30 |
2019-01-03 |
北京泰德制药股份有限公司 |
Rho-associated protein kinase inhibitor, pharmaceutical composition comprising same, and preparation method and use thereof
|
KR102563325B1
(en)
*
|
2017-06-30 |
2023-08-03 |
베이징 타이드 파마슈티컬 코퍼레이션 리미티드 |
ROH-related protein kinase inhibitors, pharmaceutical compositions containing RS-related protein kinase inhibitors, manufacturing methods and uses of pharmaceutical compositions
|
US10323023B2
(en)
|
2017-06-30 |
2019-06-18 |
Beijing Tide Pharmaceutical Co., Ltd. |
Rho-associated protein kinase inhibitor, pharmaceutical composition comprising the same, as well as preparation method and use thereof
|
US20200199136A1
(en)
*
|
2017-08-28 |
2020-06-25 |
Acurastem Inc. |
Pikfyve kinase inhibitors
|
EP3675860B1
(en)
*
|
2017-08-28 |
2023-03-08 |
Zhihong, Chen |
Substituted pyrimidines, pharmaceutical compositions and therapeutic methods thereof
|
MA49956B1
(en)
|
2017-10-27 |
2022-11-30 |
Theravance Biopharma R&D Ip Llc |
Pyrimidine compounds used as jak kinase inhibitors
|
WO2019101843A1
(en)
*
|
2017-11-23 |
2019-05-31 |
Biomed X Gmbh |
Pyrimidine derivatives as tropomyosin receptor kinase a (trka) inhibitors
|
EP3720560A4
(en)
*
|
2017-12-06 |
2022-01-05 |
Ludwig Institute for Cancer Research Ltd |
Methods of treating cancer with plk4 inhibitors
|
WO2019191092A1
(en)
|
2018-03-27 |
2019-10-03 |
Ptc Therapeutics, Inc. |
Compounds for treating huntington's disease
|
CN112367991A
(en)
*
|
2018-06-25 |
2021-02-12 |
达纳-法伯癌症研究所股份有限公司 |
TAIRE family kinase inhibitors and uses thereof
|
EP3814360A1
(en)
|
2018-06-27 |
2021-05-05 |
PTC Therapeutics, Inc. |
Heteroaryl compounds for treating huntington's disease
|
MX2020014098A
(en)
|
2018-06-27 |
2021-05-27 |
Ptc Therapeutics Inc |
Heterocyclic and heteroaryl compounds for treating huntington's disease.
|
JP7470713B2
(en)
|
2019-04-24 |
2024-04-18 |
セラヴァンス バイオファーマ アール&ディー アイピー, エルエルシー |
Ester and Carbonate Pyrimidine Compounds as JAK Kinase Inhibitors - Patent application
|
US11439641B2
(en)
|
2019-04-24 |
2022-09-13 |
Theravance Biopharma R&D Ip, Llc |
Pyrimidine JAK inhibitors for the treatment of skin diseases
|
US20220281842A1
(en)
*
|
2019-08-01 |
2022-09-08 |
Integral Biosciences Pvt. Ltd. |
Heterocyclic compounds as kinase inhibitor and uses thereof
|
US11370803B2
(en)
|
2019-09-18 |
2022-06-28 |
Takeda Pharmaceutical Company Limited |
Heteroaryl plasma kallikrein inhibitors
|
CN114728962A
(en)
|
2019-09-18 |
2022-07-08 |
武田药品工业有限公司 |
Plasma kallikrein inhibitors and uses thereof
|
CN110483493A
(en)
*
|
2019-09-19 |
2019-11-22 |
广东工业大学 |
A kind of diazole analog derivative and its preparation method and application
|
US11844754B2
(en)
|
2020-11-17 |
2023-12-19 |
Neuroderm, Ltd. |
Methods for treatment of Parkinson's disease
|
US11331293B1
(en)
|
2020-11-17 |
2022-05-17 |
Neuroderm, Ltd. |
Method for treatment of Parkinson's disease
|
US11213502B1
(en)
|
2020-11-17 |
2022-01-04 |
Neuroderm, Ltd. |
Method for treatment of parkinson's disease
|
TW202237119A
(en)
|
2020-12-10 |
2022-10-01 |
美商住友製藥腫瘤公司 |
Alk-5 inhibitors and uses thereof
|
CN117355523A
(en)
*
|
2021-03-17 |
2024-01-05 |
武田药品工业株式会社 |
Polycyclic inhibitors of plasma kallikrein
|
EP4313052A1
(en)
*
|
2021-03-26 |
2024-02-07 |
Sumitomo Pharma Oncology, Inc. |
Alk-5 inhibitors and uses thereof
|
IL308346A
(en)
|
2021-05-11 |
2024-01-01 |
Oric Pharmaceuticals Inc |
Polo like kinase 4 inhibitors
|
WO2023278326A1
(en)
|
2021-06-28 |
2023-01-05 |
Blueprint Medicines Corporation |
Cdk2 inhibitors
|
KR102692529B1
(en)
*
|
2021-07-01 |
2024-08-08 |
한국원자력의학원 |
Pharmaceutical Composition For Preventing or Treating Cancer Targeting MASTL-PP2A
|
CN116354938B
(en)
*
|
2021-12-28 |
2024-02-20 |
沈阳药科大学 |
Preparation method and application of quinazoline derivatives and analogues thereof
|
CN114276302B
(en)
*
|
2022-01-11 |
2023-07-25 |
山东百启生物医药有限公司 |
Method for preparing 2, 4-diaminoquinazoline derivative
|
WO2024003773A1
(en)
|
2022-07-01 |
2024-01-04 |
Pfizer Inc. |
2,7-naphthyridine compounds as mastl inhibitors
|
CN115403568B
(en)
*
|
2022-09-21 |
2023-09-29 |
中山大学 |
Quinazoline Aurora A covalent inhibitor and preparation method and application thereof
|
CN117736198A
(en)
*
|
2022-09-21 |
2024-03-22 |
科辉智药生物科技(深圳)有限公司 |
Macrocyclic nitrogen crown ether compounds and their use as protein kinase inhibitors
|